Revolutionizing Pharmaceutical Marketing Effectiveness with Change Management and Technology
Any analysis of future market trends starts from a thorough and accurate understanding of current market conditions, based on the most complete and reliable source of industry data - the reporting companies themselves, in their SEC filings and Annual Reports.
Forecasting the commercial performance of a drug or a pharma company is as much an art as a science, but one widely used measure of future value is the investment analyst consensus forecast, compiled from the reports published by leading financial analysts and brokers.
EvaluatePharma brings together historic sales and detailed company financials with investment analyst consensus sales forecasts in a user-friendly, online service, to deliver unique insight into the past and future performance of the pharmaceuticals and biotechnology sector.
Helping you to make better business decisions
To find out how EvaluatePharma can help you to make better business decisions, visit www.evaluatepharma.com
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.